BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lemaire M, Frémeaux-Bacchi V, Schaefer F, Choi M, Tang WH, Le Quintrec M, Fakhouri F, Taque S, Nobili F, Martinez F. Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nat Genet. 2013;45:531-536. [PMID: 23542698 DOI: 10.1038/ng.2590] [Cited by in Crossref: 317] [Cited by in F6Publishing: 261] [Article Influence: 35.2] [Reference Citation Analysis]
Number Citing Articles
1 Bajracharya P, Jain A, Baracco R, Mattoo TK, Kapur G. Atypical hemolytic uremic syndrome: a clinical conundrum. Pediatr Nephrol 2016;31:1615-24. [PMID: 27139899 DOI: 10.1007/s00467-016-3369-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
2 Lee RH, Stefanini L, Bergmeier W. Platelet Signal Transduction. Platelets. Elsevier; 2019. pp. 329-48. [DOI: 10.1016/b978-0-12-813456-6.00018-7] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
3 Ariceta G. Optimal duration of treatment with eculizumab in atypical hemolytic uremic syndrome (aHUS)-a question to be addressed in a scientific way. Pediatr Nephrol 2019;34:943-9. [PMID: 30693384 DOI: 10.1007/s00467-019-4192-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
4 Go RS, Winters JL, Leung N, Murray DL, Willrich MA, Abraham RS, Amer H, Hogan WJ, Marshall AL, Sethi S, Tran CL, Chen D, Pruthi RK, Ashrani AA, Fervenza FC, Cramer CH 2nd, Rodriguez V, Wolanskyj AP, Thomé SD, Hook CC; Mayo Clinic Complement Alternative Pathway-Thrombotic Microangiopathy Disease-Oriented Group. Thrombotic Microangiopathy Care Pathway: A Consensus Statement for the Mayo Clinic Complement Alternative Pathway-Thrombotic Microangiopathy (CAP-TMA) Disease-Oriented Group. Mayo Clin Proc 2016;91:1189-211. [PMID: 27497856 DOI: 10.1016/j.mayocp.2016.05.015] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 5.5] [Reference Citation Analysis]
5 Domingo-Gallego A, Pybus M, Bullich G, Furlano M, Ejarque-Vila L, Lorente-Grandoso L, Ruiz P, Fraga G, López González M, Piñero-Fernández JA, Rodríguez-Peña L, Llano-Rivas I, Sáez R, Bujons-Tur A, Ariceta G, Lluis G, Torra R, Ars E. Clinical utility of genetic testing in early-onset kidney disease: seven genes are the main players. Nephrol Dial Transplant 2021:gfab019. [PMID: 33532864 DOI: 10.1093/ndt/gfab019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
6 Johnson SA, Wong EK, Taylor CM. Making sense of the spectrum of glomerular disease associated with complement dysregulation. Pediatr Nephrol 2014;29:1883-94. [PMID: 23852337 DOI: 10.1007/s00467-013-2559-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
7 Zuber J, Frimat M, Caillard S, Kamar N, Gatault P, Petitprez F, Couzi L, Jourde-Chiche N, Chatelet V, Gaisne R, Bertrand D, Bamoulid J, Louis M, Sberro Soussan R, Navarro D, Westeel PF, Frimat L, Colosio C, Thierry A, Rivalan J, Albano L, Arzouk N, Cornec-Le Gall E, Claisse G, Elias M, El Karoui K, Chauvet S, Coindre JP, Rerolle JP, Tricot L, Sayegh J, Garrouste C, Charasse C, Delmas Y, Massy Z, Hourmant M, Servais A, Loirat C, Fakhouri F, Pouteil-Noble C, Peraldi MN, Legendre C, Rondeau E, Le Quintrec M, Frémeaux-Bacchi V. Use of Highly Individualized Complement Blockade Has Revolutionized Clinical Outcomes after Kidney Transplantation and Renal Epidemiology of Atypical Hemolytic Uremic Syndrome. J Am Soc Nephrol 2019;30:2449-63. [PMID: 31575699 DOI: 10.1681/ASN.2019040331] [Cited by in Crossref: 27] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
8 Cheung V, Trachtman H. Hemolytic uremic syndrome: toxins, vessels, and inflammation. Front Med (Lausanne) 2014;1:42. [PMID: 25593915 DOI: 10.3389/fmed.2014.00042] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
9 Alasfar S, Alachkar N. Atypical hemolytic uremic syndrome post-kidney transplantation: two case reports and review of the literature. Front Med (Lausanne) 2014;1:52. [PMID: 25593925 DOI: 10.3389/fmed.2014.00052] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
10 Stokman MF, Renkema KY, Giles RH, Schaefer F, Knoers NV, van Eerde AM. The expanding phenotypic spectra of kidney diseases: insights from genetic studies. Nat Rev Nephrol 2016;12:472-83. [PMID: 27374918 DOI: 10.1038/nrneph.2016.87] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 6.0] [Reference Citation Analysis]
11 Sheerin NS, Kavanagh D, Goodship TH, Johnson S. A national specialized service in England for atypical haemolytic uraemic syndrome-the first year's experience. QJM 2016;109:27-33. [PMID: 25899302 DOI: 10.1093/qjmed/hcv082] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 7.3] [Reference Citation Analysis]
12 Yoshida Y, Miyata T, Matsumoto M, Shirotani-Ikejima H, Uchida Y, Ohyama Y, Kokubo T, Fujimura Y. A novel quantitative hemolytic assay coupled with restriction fragment length polymorphisms analysis enabled early diagnosis of atypical hemolytic uremic syndrome and identified unique predisposing mutations in Japan. PLoS One 2015;10:e0124655. [PMID: 25951460 DOI: 10.1371/journal.pone.0124655] [Cited by in Crossref: 33] [Cited by in F6Publishing: 20] [Article Influence: 4.7] [Reference Citation Analysis]
13 Furmańczyk-Zawiska A, Kubiak-Dydo A, Użarowska-Gąska E, Kotlarek-Łysakowska M, Salata K, Kolanowska M, Świerniak M, Gaj P, Leszczyńska B, Daniel M, Jażdżewski K, Durlik M, Wójcicka A. Compound Haplotype Variants in CFH and CD46 Genes Determine Clinical Outcome of Atypical Hemolytic Uremic Syndrome (aHUS)-A Series of Cases from a Single Family. J Pers Med 2021;11:304. [PMID: 33920896 DOI: 10.3390/jpm11040304] [Reference Citation Analysis]
14 Vijayan KV. DGKE disruption ditches complement and drives p38 signaling. Blood 2015;125:898-9. [PMID: 25655457 DOI: 10.1182/blood-2014-12-617589] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
15 Blasco Pelicano M, Rodríguez de Córdoba S, Campistol Plana JM. Síndrome hemolítico urémico atípico. Medicina Clínica 2015;145:438-45. [DOI: 10.1016/j.medcli.2014.08.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
16 Gavriilaki E, Brodsky RA. Complementopathies and precision medicine. J Clin Invest 2020;130:2152-63. [PMID: 32310222 DOI: 10.1172/JCI136094] [Cited by in Crossref: 36] [Cited by in F6Publishing: 20] [Article Influence: 36.0] [Reference Citation Analysis]
17 Mannerås-Holm L, Schönke M, Brozinick JT, Vetterli L, Bui HH, Sanders P, Nascimento EBM, Björnholm M, Chibalin AV, Zierath JR. Diacylglycerol kinase ε deficiency preserves glucose tolerance and modulates lipid metabolism in obese mice. J Lipid Res 2017;58:907-15. [PMID: 28246337 DOI: 10.1194/jlr.M074443] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 2.6] [Reference Citation Analysis]
18 Bezdíčka M, Štolbová Š, Seeman T, Cinek O, Malina M, Šimánková N, Průhová Š, Zieg J. Genetic diagnosis of steroid-resistant nephrotic syndrome in a longitudinal collection of Czech and Slovak patients: a high proportion of causative variants in NUP93. Pediatr Nephrol 2018;33:1347-63. [DOI: 10.1007/s00467-018-3950-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
19 Raina R, Vijayvargiya N, Khooblall A, Melachuri M, Deshpande S, Sharma D, Mathur K, Arora M, Sethi SK, Sandhu S. Pediatric Atypical Hemolytic Uremic Syndrome Advances. Cells 2021;10:3580. [PMID: 34944087 DOI: 10.3390/cells10123580] [Reference Citation Analysis]
20 Haller H. Thrombotische Mikroangiopathie und Niere. Nephrologe 2019;14:100-7. [DOI: 10.1007/s11560-019-0320-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
21 Okumi M, Tanabe K. Prevention and treatment of atypical haemolytic uremic syndrome after kidney transplantation. Nephrology (Carlton) 2016;21 Suppl 1:9-13. [PMID: 26988663 DOI: 10.1111/nep.12776] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
22 Gulati A, Dahl N, Tufro A. Inherited glomerular diseases in the gilded age of genomic advancements. Pediatr Nephrol 2020;35:959-68. [PMID: 31049720 DOI: 10.1007/s00467-019-04266-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
23 Pang X, Luo H, Chai Y, Wang X, Sun L, He L, Chen P, Wu H, Yang T. A 1.6-Mb microdeletion in chromosome 17q22 leads to NOG-related symphalangism spectrum disorder without intellectual disability. PLoS One 2015;10:e0120816. [PMID: 25815513 DOI: 10.1371/journal.pone.0120816] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
24 Brocklebank V, Kumar G, Howie AJ, Chandar J, Milford DV, Craze J, Evans J, Finlay E, Freundlich M, Gale DP, Inward C, Mraz M, Jones C, Wong W, Marks SD, Connolly J, Corner BM, Smith-Jackson K, Walsh PR, Marchbank KJ, Harris CL, Wilson V, Wong EKS, Malina M, Johnson S, Sheerin NS, Kavanagh D. Long-term outcomes and response to treatment in diacylglycerol kinase epsilon nephropathy. Kidney Int 2020;97:1260-74. [PMID: 32386968 DOI: 10.1016/j.kint.2020.01.045] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
25 Bozelli JC Jr, Aulakh SS, Epand RM. Membrane shape as determinant of protein properties. Biophys Chem 2021;273:106587. [PMID: 33865153 DOI: 10.1016/j.bpc.2021.106587] [Reference Citation Analysis]
26 Jennings W, Doshi S, Hota PK, Prodeus A, Black S, Epand RM. Expression, Purification, and Properties of a Human Arachidonoyl-Specific Isoform of Diacylglycerol Kinase. Biochemistry 2017;56:1337-47. [PMID: 28199087 DOI: 10.1021/acs.biochem.6b01193] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
27 Lu S, Liu S, Wietelmann A, Kojonazarov B, Atzberger A, Tang C, Schermuly RT, Gröne HJ, Offermanns S. Developmental vascular remodeling defects and postnatal kidney failure in mice lacking Gpr116 (Adgrf5) and Eltd1 (Adgrl4). PLoS One 2017;12:e0183166. [PMID: 28806758 DOI: 10.1371/journal.pone.0183166] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
28 Brocklebank V, Kavanagh D. Protecting the kidney from complement: atypical haemolytic uraemic syndrome. Clin Med (Lond) 2014;14 Suppl 6:s89-94. [PMID: 25468928 DOI: 10.7861/clinmedicine.14-6-s89] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
29 Trachtman H. HUS and TTP in Children. Pediatr Clin North Am 2013;60:1513-26. [PMID: 24237985 DOI: 10.1016/j.pcl.2013.08.007] [Cited by in Crossref: 25] [Cited by in F6Publishing: 13] [Article Influence: 3.1] [Reference Citation Analysis]
30 Rafat C, Coppo P, Fakhouri F, Frémeaux-Bacchi V, Loirat C, Zuber J, Rondeau E. [Hemolytic and uremic syndrome and related thrombotic microangiopathies: Epidemiology, pathophysiology and clinics]. Rev Med Interne 2017;38:817-24. [PMID: 28711159 DOI: 10.1016/j.revmed.2017.06.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
31 Rubio-Navarro A, Sanchez-Niño MD, Guerrero-Hue M, García-Caballero C, Gutiérrez E, Yuste C, Sevillano Á, Praga M, Egea J, Román E, Cannata P, Ortega R, Cortegano I, de Andrés B, Gaspar ML, Cadenas S, Ortiz A, Egido J, Moreno JA. Podocytes are new cellular targets of haemoglobin-mediated renal damage. J Pathol 2018;244:296-310. [PMID: 29205354 DOI: 10.1002/path.5011] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 7.3] [Reference Citation Analysis]
32 Greenbaum LA. Atypical Hemolytic Uremic Syndrome. Advances in Pediatrics 2014;61:335-56. [DOI: 10.1016/j.yapd.2014.04.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
33 Brocklebank V, Johnson S, Sheerin TP, Marks SD, Gilbert RD, Tyerman K, Kinoshita M, Awan A, Kaur A, Webb N, Hegde S, Finlay E, Fitzpatrick M, Walsh PR, Wong EKS, Booth C, Kerecuk L, Salama AD, Almond M, Inward C, Goodship TH, Sheerin NS, Marchbank KJ, Kavanagh D. Factor H autoantibody is associated with atypical hemolytic uremic syndrome in children in the United Kingdom and Ireland. Kidney Int 2017;92:1261-71. [PMID: 28750931 DOI: 10.1016/j.kint.2017.04.028] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
34 Lee JM, Park YS, Lee JH, Park SJ, Shin JI, Park YH, Yoo KH, Cho MH, Kim SY, Kim SH, Namgoong MK, Lee SJ, Lee JH, Cho HY, Han KH, Kang HG, Ha IS, Bae JS, Kim NK, Park WY, Cheong HI. Atypical hemolytic uremic syndrome: Korean pediatric series. Pediatr Int 2015;57:431-8. [PMID: 25443527 DOI: 10.1111/ped.12549] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 3.7] [Reference Citation Analysis]
35 Takemon Y, Wright V, Davenport B, Gatti DM, Sheehan SM, Letson K, Savage HS, Lennon R, Korstanje R. Uncovering Modifier Genes of X-Linked Alport Syndrome Using a Novel Multiparent Mouse Model. J Am Soc Nephrol 2021;32:1961-73. [PMID: 34045313 DOI: 10.1681/ASN.2020060777] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
36 Enjeti AK, de Malmanche T, Chapman K, Ziolkowski A. Genomic investigation of inherited thrombotic microangiopathy-aHUS and TTP. Int J Lab Hematol 2020;42 Suppl 1:33-40. [PMID: 32543063 DOI: 10.1111/ijlh.13201] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
37 Torra R, Furlano M, Ortiz A, Ars E. Genetic kidney diseases as an underrecognized cause of chronic kidney disease: the key role of international registry reports. Clin Kidney J 2021;14:1879-85. [PMID: 34345410 DOI: 10.1093/ckj/sfab056] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Yoshida Y, Kato H, Ikeda Y, Nangaku M. Pathogenesis of Atypical Hemolytic Uremic Syndrome. J Atheroscler Thromb 2019;26:99-110. [PMID: 30393246 DOI: 10.5551/jat.RV17026] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
39 Afshar-Kharghan V. Atypical hemolytic uremic syndrome. Hematology Am Soc Hematol Educ Program 2016;2016:217-25. [PMID: 27913483 DOI: 10.1182/asheducation-2016.1.217] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 4.4] [Reference Citation Analysis]
40 Padmanabhan A, Connelly-Smith L, Aqui N, Balogun RA, Klingel R, Meyer E, Pham HP, Schneiderman J, Witt V, Wu Y, Zantek ND, Dunbar NM, Schwartz GEJ. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue. J Clin Apher. 2019;34:171-354. [PMID: 31180581 DOI: 10.1002/jca.21705] [Cited by in Crossref: 314] [Cited by in F6Publishing: 277] [Article Influence: 104.7] [Reference Citation Analysis]
41 Nozal P, Bernabéu-herrero ME, Uzonyi B, Szilágyi Á, Hyvärinen S, Prohászka Z, Jokiranta TS, Sánchez-corral P, López-trascasa M, Józsi M. Heterogeneity but individual constancy of epitopes, isotypes and avidity of factor H autoantibodies in atypical hemolytic uremic syndrome. Molecular Immunology 2016;70:47-55. [DOI: 10.1016/j.molimm.2015.12.005] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
42 Pollak MR, Quaggin SE, Hoenig MP, Dworkin LD. The glomerulus: the sphere of influence. Clin J Am Soc Nephrol 2014;9:1461-9. [PMID: 24875196 DOI: 10.2215/CJN.09400913] [Cited by in Crossref: 61] [Cited by in F6Publishing: 22] [Article Influence: 7.6] [Reference Citation Analysis]
43 Conway EM. HUS and the case for complement. Blood. 2015;126:2085-2090. [PMID: 26396094 DOI: 10.1182/blood-2015-03-569277] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
44 Teoh CW, Riedl M, Licht C. The alternative pathway of complement and the thrombotic microangiopathies. Transfus Apher Sci. 2016;54:220-231. [PMID: 27160864 DOI: 10.1016/j.transci.2016.04.012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
45 Xiao H, Hildebrandt F. Whole exome sequencing identifies monogenic forms of nephritis in a previously unsolved cohort of children with steroid-resistant nephrotic syndrome and hematuria. Pediatr Nephrol 2021. [PMID: 34762194 DOI: 10.1007/s00467-021-05312-4] [Reference Citation Analysis]
46 Brocklebank V, Kavanagh D. Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea. Clin Kidney J 2017;10:600-24. [PMID: 28980670 DOI: 10.1093/ckj/sfx081] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
47 Bogdał A, Badeński A, Pac M, Wójcicka A, Badeńska M, Didyk A, Trembecka-Dubel E, Dąbrowska-Leonik N, Walaszczyk M, Matysiak N, Morawiec-Knysak A, Szczepański T, Szczepańska M. Atypical Hemolytic Uremic Syndrome (aHUS) and Adenosine Deaminase (ADA)-Deficient Severe Combined Immunodeficiency (SCID)-Two Diseases That Exacerbate Each Other: Case Report. Int J Mol Sci 2021;22:9479. [PMID: 34502390 DOI: 10.3390/ijms22179479] [Reference Citation Analysis]
48 Fujisawa M, Kato H, Yoshida Y, Usui T, Takata M, Fujimoto M, Wada H, Uchida Y, Kokame K, Matsumoto M, Fujimura Y, Miyata T, Nangaku M. Clinical characteristics and genetic backgrounds of Japanese patients with atypical hemolytic uremic syndrome. Clin Exp Nephrol 2018;22:1088-99. [PMID: 29511899 DOI: 10.1007/s10157-018-1549-3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
49 Frazer-abel A, Sepiashvili L, Mbughuni M, Willrich M. Overview of Laboratory Testing and Clinical Presentations of Complement Deficiencies and Dysregulation. Elsevier; 2016. pp. 1-75. [DOI: 10.1016/bs.acc.2016.06.001] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
50 Kuppachi S, Smith RJH, Thomas CP. Evaluation of Genetic Renal Diseases in Potential Living Kidney Donors. Curr Transpl Rep 2015;2:1-14. [DOI: 10.1007/s40472-014-0042-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
51 Günay N, Pınarbaşı AS, Doğan ME, Yel S, Balaban AG, Dursun İ, Eken A, Akgün H, Dündar M, Poyrazoğlu MH. A rare cause of membranoproliferative patterns of injury in siblings with steroid-resistant nephrotic syndrome: Answers. Pediatr Nephrol 2021. [PMID: 34185135 DOI: 10.1007/s00467-021-05154-0] [Reference Citation Analysis]
52 Gaut JP, Jain S, Pfeifer JD, Vigh-Conrad KA, Corliss M, Sharma MK, Heusel JW, Cottrell CE. Routine use of clinical exome-based next-generation sequencing for evaluation of patients with thrombotic microangiopathies. Mod Pathol 2017;30:1739-47. [PMID: 28752844 DOI: 10.1038/modpathol.2017.90] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
53 Harris CL, Pouw RB, Kavanagh D, Sun R, Ricklin D. Developments in anti-complement therapy; from disease to clinical trial. Mol Immunol 2018;102:89-119. [PMID: 30121124 DOI: 10.1016/j.molimm.2018.06.008] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 10.3] [Reference Citation Analysis]
54 Schröder-Braunstein J, Kirschfink M. Complement deficiencies and dysregulation: Pathophysiological consequences, modern analysis, and clinical management. Mol Immunol 2019;114:299-311. [PMID: 31421540 DOI: 10.1016/j.molimm.2019.08.002] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
55 Sauvètre G, Grange S, Froissart A, Veyradier A, Coppo P, Benhamou Y. La révolution des anticorps monoclonaux dans la prise en charge des microangiopathies thrombotiques. La Revue de Médecine Interne 2015;36:328-38. [DOI: 10.1016/j.revmed.2014.10.364] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
56 Vilarinho S, Sari S, Yilmaz G, Stiegler AL, Boggon TJ, Jain D, Akyol G, Dalgic B, Günel M, Lifton RP. Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension. Hepatology 2016;63:1977-86. [PMID: 26874653 DOI: 10.1002/hep.28499] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
57 Jourde-Chiche N, Fakhouri F, Dou L, Bellien J, Burtey S, Frimat M, Jarrot PA, Kaplanski G, Le Quintrec M, Pernin V, Rigothier C, Sallée M, Fremeaux-Bacchi V, Guerrot D, Roumenina LT. Endothelium structure and function in kidney health and disease. Nat Rev Nephrol 2019;15:87-108. [PMID: 30607032 DOI: 10.1038/s41581-018-0098-z] [Cited by in Crossref: 104] [Cited by in F6Publishing: 98] [Article Influence: 34.7] [Reference Citation Analysis]
58 Java A. Peri- and Post-operative Evaluation and Management of Atypical Hemolytic Uremic Syndrome (aHUS) in Kidney Transplantation. Adv Chronic Kidney Dis 2020;27:128-37. [PMID: 32553245 DOI: 10.1053/j.ackd.2019.11.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
59 Gaggl M, Aigner C, Sunder-Plassmann G, Schmidt A. [Thrombotic microangiopathy : Relevant new aspects for intensive care physicians]. Med Klin Intensivmed Notfmed 2016;111:434-9. [PMID: 27255224 DOI: 10.1007/s00063-016-0176-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
60 Greenbaum LA, Fila M, Ardissino G, Al-Akash SI, Evans J, Henning P, Lieberman KV, Maringhini S, Pape L, Rees L, van de Kar NC, Vande Walle J, Ogawa M, Bedrosian CL, Licht C. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Kidney Int 2016;89:701-11. [PMID: 26880462 DOI: 10.1016/j.kint.2015.11.026] [Cited by in Crossref: 141] [Cited by in F6Publishing: 119] [Article Influence: 23.5] [Reference Citation Analysis]
61 Hayashi D, Yagi K, Song C, Ueda S, Yamanoue M, Topham M, Suzaki T, Saito N, Emoto N, Shirai Y. Diacylglycerol Kinase alpha is Involved in the Vitamin E-Induced Amelioration of Diabetic Nephropathy in Mice. Sci Rep 2017;7:2597. [PMID: 28572624 DOI: 10.1038/s41598-017-02354-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
62 McFarlane PA, Bitzan M, Broome C, Baran D, Garland J, Girard LP, Grewal K, Lapeyraque AL, Patriquin CJ, Pavenski K, Licht C. Making the Correct Diagnosis in Thrombotic Microangiopathy: A Narrative Review. Can J Kidney Health Dis 2021;8:20543581211008707. [PMID: 33996107 DOI: 10.1177/20543581211008707] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
63 Walsh PR, Johnson S, Brocklebank V, Salvatore J, Christian M, Kavanagh D. Glucose-6-Phosphate Dehydrogenase Deficiency Mimicking Atypical Hemolytic Uremic Syndrome. Am J Kidney Dis 2018;71:287-90. [PMID: 29248304 DOI: 10.1053/j.ajkd.2017.08.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
64 Meyers KE, Liapis H, Atta MG. American Society of Nephrology clinical pathological conference. Clin J Am Soc Nephrol 2014;9:818-28. [PMID: 24651072 DOI: 10.2215/CJN.12481213] [Reference Citation Analysis]
65 Besbas N, Gulhan B, Soylemezoglu O, Ozcakar ZB, Korkmaz E, Hayran M, Ozaltin F. Turkish pediatric atypical hemolytic uremic syndrome registry: initial analysis of 146 patients. BMC Nephrol. 2017;18:6. [PMID: 28056875 DOI: 10.1186/s12882-016-0420-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 3.6] [Reference Citation Analysis]
66 Riedl M, Hofer J, Giner T, Rosales A, Häffner K, Simonetti GD, Walden U, Maier T, Heininger D, Jeller V, Weiss G, van den Heuvel L, Zimmerhackl LB, Würzner R, Jungraithmayr TC. Novel biomarker and easy to perform ELISA for monitoring complement inhibition in patients with atypical hemolytic uremic syndrome treated with eculizumab. J Immunol Methods 2016;435:60-7. [PMID: 27238216 DOI: 10.1016/j.jim.2016.05.009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
67 Rawish E, Sauter M, Sauter R, Nording H, Langer HF. Complement, inflammation and thrombosis. Br J Pharmacol 2021;178:2892-904. [PMID: 33817781 DOI: 10.1111/bph.15476] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
68 Merida I, Arranz-Nicolás J, Torres-Ayuso P, Ávila-Flores A. Diacylglycerol Kinase Malfunction in Human Disease and the Search for Specific Inhibitors. Handb Exp Pharmacol 2020;259:133-62. [PMID: 31227890 DOI: 10.1007/164_2019_221] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
69 Wortmann SB, Espeel M, Almeida L, Reimer A, Bosboom D, Roels F, de Brouwer AP, Wevers RA. Inborn errors of metabolism in the biosynthesis and remodelling of phospholipids. J Inherit Metab Dis 2015;38:99-110. [DOI: 10.1007/s10545-014-9759-7] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 3.5] [Reference Citation Analysis]
70 Noris M, Remuzzi G. Managing and preventing atypical hemolytic uremic syndrome recurrence after kidney transplantation. Curr Opin Nephrol Hypertens. 2013;22:704-712. [PMID: 24076560 DOI: 10.1097/mnh.0b013e328365b3fe] [Cited by in Crossref: 40] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
71 Nestor JG, Groopman EE, Gharavi AG. Towards precision nephrology: the opportunities and challenges of genomic medicine. J Nephrol 2018;31:47-60. [PMID: 29043570 DOI: 10.1007/s40620-017-0448-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
72 Krishnappa V, Gupta M, Elrifai M, Moftakhar B, Ensley MJ, Vachharajani TJ, Sethi SK, Raina R. Atypical Hemolytic Uremic Syndrome: A Meta-Analysis of Case Reports Confirms the Prevalence of Genetic Mutations and the Shift of Treatment Regimens: Meta-Analysis of Atypical HUS Case Reports. Therapeutic Apheresis and Dialysis 2018;22:178-88. [DOI: 10.1111/1744-9987.12641] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
73 Epand RM, So V, Jennings W, Khadka B, Gupta RS, Lemaire M. Diacylglycerol Kinase-ε: Properties and Biological Roles. Front Cell Dev Biol 2016;4:112. [PMID: 27803897 DOI: 10.3389/fcell.2016.00112] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
74 Cofiell R, Kukreja A, Bedard K, Yan Y, Mickle AP, Ogawa M, Bedrosian CL, Faas SJ. Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS. Blood 2015;125:3253-62. [PMID: 25833956 DOI: 10.1182/blood-2014-09-600411] [Cited by in Crossref: 109] [Cited by in F6Publishing: 96] [Article Influence: 15.6] [Reference Citation Analysis]
75 Zheng XL. ADAMTS13 and von Willebrand factor in thrombotic thrombocytopenic purpura. Annu Rev Med 2015;66:211-25. [PMID: 25587650 DOI: 10.1146/annurev-med-061813-013241] [Cited by in Crossref: 92] [Cited by in F6Publishing: 81] [Article Influence: 13.1] [Reference Citation Analysis]
76 Berger BE. Atypical hemolytic uremic syndrome: a syndrome in need of clarity. Clin Kidney J 2019;12:338-47. [PMID: 31198222 DOI: 10.1093/ckj/sfy066] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
77 Hu H, Nagra A, Haq MR, Gilbert RD. Eculizumab in atypical haemolytic uraemic syndrome with severe cardiac and neurological involvement. Pediatr Nephrol 2014;29:1103-6. [DOI: 10.1007/s00467-013-2709-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
78 Kavanagh D, Raman S, Sheerin NS. Management of hemolytic uremic syndrome. F1000Prime Rep 2014;6:119. [PMID: 25580273 DOI: 10.12703/P6-119] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
79 Bacchetta J, Cochat P. Primary disease recurrence—effects on paediatric renal transplantation outcomes. Nat Rev Nephrol 2015;11:371-84. [PMID: 25917555 DOI: 10.1038/nrneph.2015.54] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
80 Azukaitis K, Simkova E, Majid MA, Galiano M, Benz K, Amann K, Bockmeyer C, Gajjar R, Meyers KE, Cheong HI, Lange-Sperandio B, Jungraithmayr T, Frémeaux-Bacchi V, Bergmann C, Bereczki C, Miklaszewska M, Csuka D, Prohászka Z, Killen P, Gipson P, Sampson MG, Lemaire M, Schaefer F. The Phenotypic Spectrum of Nephropathies Associated with Mutations in Diacylglycerol Kinase ε. J Am Soc Nephrol 2017;28:3066-75. [PMID: 28526779 DOI: 10.1681/ASN.2017010031] [Cited by in Crossref: 28] [Cited by in F6Publishing: 13] [Article Influence: 5.6] [Reference Citation Analysis]
81 Sánchez Chinchilla D, Pinto S, Hoppe B, Adragna M, Lopez L, Justa Roldan ML, Peña A, Lopez Trascasa M, Sánchez-Corral P, Rodríguez de Córdoba S. Complement mutations in diacylglycerol kinase-ε-associated atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 2014;9:1611-9. [PMID: 25135762 DOI: 10.2215/CJN.01640214] [Cited by in Crossref: 51] [Cited by in F6Publishing: 27] [Article Influence: 6.4] [Reference Citation Analysis]
82 D'souza K, Epand RM. Enrichment of phosphatidylinositols with specific acyl chains. Biochimica et Biophysica Acta (BBA) - Biomembranes 2014;1838:1501-8. [DOI: 10.1016/j.bbamem.2013.10.003] [Cited by in Crossref: 60] [Cited by in F6Publishing: 57] [Article Influence: 7.5] [Reference Citation Analysis]
83 Jamme M, Raimbourg Q, Chauveau D, Seguin A, Presne C, Perez P, Gobert P, Wynckel A, Provôt F, Delmas Y, Mousson C, Servais A, Vrigneaud L, Veyradier A, Rondeau E, Coppo P; French Thrombotic Microangiopathies Reference Centre. Predictive features of chronic kidney disease in atypical haemolytic uremic syndrome. PLoS One 2017;12:e0177894. [PMID: 28542627 DOI: 10.1371/journal.pone.0177894] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
84 Li AS, Ingham JF, Lennon R. Genetic Disorders of the Glomerular Filtration Barrier. Clin J Am Soc Nephrol 2020;15:1818-28. [PMID: 32205319 DOI: 10.2215/CJN.11440919] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
85 Kollbrunner L, Hirt-Minkowski P, Sanz J, Bresin E, Neuhaus TJ, Hopfer H, Jehle AW. Case Report: Lipoprotein Glomerulopathy Complicated by Atypical Hemolytic Uremic Syndrome. Front Med (Lausanne) 2021;8:679048. [PMID: 34150810 DOI: 10.3389/fmed.2021.679048] [Reference Citation Analysis]
86 Xiao C, Rossignol F, Vaz FM, Ferreira CR. Inherited disorders of complex lipid metabolism: A clinical review. J Inherit Metab Dis 2021;44:809-25. [PMID: 33594685 DOI: 10.1002/jimd.12369] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
87 Yang F, Petsalaki E, Rolland T, Hill DE, Vidal M, Roth FP. Protein domain-level landscape of cancer-type-specific somatic mutations. PLoS Comput Biol 2015;11:e1004147. [PMID: 25794154 DOI: 10.1371/journal.pcbi.1004147] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 6.7] [Reference Citation Analysis]
88 Osborne AJ, Breno M, Borsa NG, Bu F, Frémeaux-Bacchi V, Gale DP, van den Heuvel LP, Kavanagh D, Noris M, Pinto S, Rallapalli PM, Remuzzi G, Rodríguez de Cordoba S, Ruiz A, Smith RJH, Vieira-Martins P, Volokhina E, Wilson V, Goodship THJ, Perkins SJ. Statistical Validation of Rare Complement Variants Provides Insights into the Molecular Basis of Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy. J Immunol 2018;200:2464-78. [PMID: 29500241 DOI: 10.4049/jimmunol.1701695] [Cited by in Crossref: 68] [Cited by in F6Publishing: 62] [Article Influence: 17.0] [Reference Citation Analysis]
89 Burns KD, Levin A, Fowler E, Butcher L, Turcotte M, Makarchuk MJ, Macaluso B, Larivière V, Sherman PM. The KRESCENT Program (2005-2015): An Evaluation of the State of Kidney Research Training in Canada. Can J Kidney Health Dis 2017;4:2054358117693354. [PMID: 28270932 DOI: 10.1177/2054358117693354] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
90 Merle NS, Noe R, Halbwachs-Mecarelli L, Fremeaux-Bacchi V, Roumenina LT. Complement System Part II: Role in Immunity. Front Immunol 2015;6:257. [PMID: 26074922 DOI: 10.3389/fimmu.2015.00257] [Cited by in Crossref: 353] [Cited by in F6Publishing: 385] [Article Influence: 50.4] [Reference Citation Analysis]
91 Mella A, Messina M, Lavacca A, Biancone L. Complement cascade and kidney transplantation: The rediscovery of an ancient enemy. World J Transplant 2014; 4(3): 168-175 [PMID: 25346889 DOI: 10.5500/wjt.v4.i3.168] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
92 Dixon BP, Gruppo RA. Atypical Hemolytic Uremic Syndrome. Pediatric Clinics of North America 2018;65:509-25. [DOI: 10.1016/j.pcl.2018.02.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
93 Barnum SR. Complement: A primer for the coming therapeutic revolution. Pharmacol Ther 2017;172:63-72. [PMID: 27914981 DOI: 10.1016/j.pharmthera.2016.11.014] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 6.0] [Reference Citation Analysis]
94 Mele C, Remuzzi G, Noris M. Hemolytic uremic syndrome. Semin Immunopathol 2014;36:399-420. [PMID: 24526222 DOI: 10.1007/s00281-014-0416-x] [Cited by in Crossref: 92] [Cited by in F6Publishing: 67] [Article Influence: 11.5] [Reference Citation Analysis]
95 Mcgeer PL, Lee M, Mcgeer EG. A review of human diseases caused or exacerbated by aberrant complement activation. Neurobiology of Aging 2017;52:12-22. [DOI: 10.1016/j.neurobiolaging.2016.12.017] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 6.0] [Reference Citation Analysis]
96 Vieira-martins P, El Sissy C, Bordereau P, Gruber A, Rosain J, Fremeaux-bacchi V. Defining the genetics of thrombotic microangiopathies. Transfusion and Apheresis Science 2016;54:212-9. [DOI: 10.1016/j.transci.2016.04.011] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 5.3] [Reference Citation Analysis]
97 Piedrafita A, Ribes D, Cointault O, Chauveau D, Faguer S, Huart A. Plasma exchange and thrombotic microangiopathies: From pathophysiology to clinical practice. Transfus Apher Sci 2020;59:102990. [PMID: 33272850 DOI: 10.1016/j.transci.2020.102990] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
98 Miyata T, Uchida Y, Ohta T, Urayama K, Yoshida Y, Fujimura Y. Atypical haemolytic uraemic syndrome in a Japanese patient with DGKE genetic mutations. Thromb Haemost 2015;114:862-3. [PMID: 26018111 DOI: 10.1160/TH15-01-0007] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
99 Basnayake BMDB, Wazil AWM, Nanayakkara N, Samarakoon SMDK, Senavirathne EMSK, Thangarajah BUEWDR, Karunasena N, Mahanama RMBSS. Atypical hemolytic uremic syndrome: a case report. J Med Case Rep 2020;14:11. [PMID: 31928535 DOI: 10.1186/s13256-019-2334-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
100 Scully M, Goodship T. How I treat thrombotic thrombocytopenic purpura and atypical haemolytic uraemic syndrome. Br J Haematol. 2014;164:759-766. [PMID: 24387053 DOI: 10.1111/bjh.12718] [Cited by in Crossref: 101] [Cited by in F6Publishing: 82] [Article Influence: 12.6] [Reference Citation Analysis]
101 Gavriilaki E, Yuan X, Ye Z, Ambinder AJ, Shanbhag SP, Streiff MB, Kickler TS, Moliterno AR, Sperati CJ, Brodsky RA. Modified Ham test for atypical hemolytic uremic syndrome. Blood 2015;125:3637-46. [PMID: 25862562 DOI: 10.1182/blood-2015-02-629683] [Cited by in Crossref: 64] [Cited by in F6Publishing: 59] [Article Influence: 9.1] [Reference Citation Analysis]
102 Bruneau S, Néel M, Roumenina LT, Frimat M, Laurent L, Frémeaux-Bacchi V, Fakhouri F. Loss of DGKε induces endothelial cell activation and death independently of complement activation. Blood 2015;125:1038-46. [PMID: 25498910 DOI: 10.1182/blood-2014-06-579953] [Cited by in Crossref: 59] [Cited by in F6Publishing: 54] [Article Influence: 7.4] [Reference Citation Analysis]
103 Çakar N, Ozcakar Z, Ozaltin F, Koyun M, Celikel acar B, Bahat E, Gulhan B, Korkmaz E, Yurt A, Yılmaz S, Soylemezoglu O, Yalcinkaya F. Atypical Hemolytic Uremic Syndrome in Children Aged <2 Years. Nephron 2018;139:211-8. [DOI: 10.1159/000487609] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
104 Sridharan M, Go RS, Willrich MAV. Atypical hemolytic uremic syndrome: Review of clinical presentation, diagnosis and management. J Immunol Methods 2018;461:15-22. [PMID: 30031798 DOI: 10.1016/j.jim.2018.07.006] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
105 Fox LC, Cohney SJ, Kausman JY, Shortt J, Hughes PD, Wood EM, Isbel NM, de Malmanche T, Durkan A, Hissaria P, Blombery P, Barbour TD. Consensus opinion on diagnosis and management of thrombotic microangiopathy in Australia and New Zealand: Thrombotic microangiopathy in Australia/New Zealand. Intern Med J 2018;48:624-36. [DOI: 10.1111/imj.13804] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
106 Ipe TS, Pham HP, Williams LA. Critical updates in the 7 th edition of the American Society for Apheresis guidelines. J Clin Apher 2018;33:78-94. [DOI: 10.1002/jca.21562] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
107 Pierce R, Ji W, Chan EC, Xie Z, Long LM, Khokha M, Lakhani S, Druey KM. Whole-Exome Sequencing of Adult and Pediatric Cohorts of the Rare Vascular Disorder Systemic Capillary Leak Syndrome. Shock 2019;52:183-90. [PMID: 30289850 DOI: 10.1097/SHK.0000000000001254] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
108 Berthaud R, Heidet L, Oualha M, Brat R, Talmud D, Garaix F, Rabant M, Frémeaux-Bacchi V, Antignac C, Boyer O, Dorval G. Atypical severe early-onset nephrotic syndrome: Answers. Pediatr Nephrol 2022. [PMID: 35507148 DOI: 10.1007/s00467-022-05537-x] [Reference Citation Analysis]
109 Licht C, Ardissino G, Ariceta G, Cohen D, Cole JA, Gasteyger C, Greenbaum LA, Johnson S, Ogawa M, Schaefer F, Vande Walle J, Frémeaux-Bacchi V. The global aHUS registry: methodology and initial patient characteristics. BMC Nephrol 2015;16:207. [PMID: 26654630 DOI: 10.1186/s12882-015-0195-1] [Cited by in Crossref: 39] [Cited by in F6Publishing: 32] [Article Influence: 5.6] [Reference Citation Analysis]
110 Ardissino G, Longhi S, Porcaro L, Pintarelli G, Strumbo B, Capone V, Cresseri D, Loffredo G, Tel F, Salardi S, Sgarbanti M, Martelli L, Rodrigues EM, Borsa-Ghiringhelli N, Montini G, Seia M, Cugno M, Carfagna F, Consonni D, Tedeschi S. Risk of Atypical HUS Among Family Members of Patients Carrying Complement Regulatory Gene Abnormality. Kidney Int Rep 2021;6:1614-21. [PMID: 34169201 DOI: 10.1016/j.ekir.2021.03.885] [Reference Citation Analysis]
111 Bozelli JC Jr, Epand RM. Specificity of Acyl Chain Composition of Phosphatidylinositols. Proteomics 2019;19:e1900138. [PMID: 31381272 DOI: 10.1002/pmic.201900138] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
112 Aradottir SS, Kristoffersson AC, Roumenina LT, Bjerre A, Kashioulis P, Palsson R, Karpman D. Factor D Inhibition Blocks Complement Activation Induced by Mutant Factor B Associated With Atypical Hemolytic Uremic Syndrome and Membranoproliferative Glomerulonephritis. Front Immunol 2021;12:690821. [PMID: 34177949 DOI: 10.3389/fimmu.2021.690821] [Reference Citation Analysis]
113 Foster MH, Ord JR. Emerging immunotherapies for autoimmune kidney disease. Hum Vaccin Immunother 2019;15:876-90. [PMID: 30550361 DOI: 10.1080/21645515.2018.1555569] [Reference Citation Analysis]
114 Wong E, Challis R, Sheerin N, Johnson S, Kavanagh D, Goodship TH. Patient stratification and therapy in atypical haemolytic uraemic syndrome (aHUS). Immunobiology 2016;221:715-8. [DOI: 10.1016/j.imbio.2015.05.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
115 Lee M, Lee G, Kang HG, Suh JS. New susceptible locus, rs9428555, is associated with pediatric-onset immunoglobulin A nephropathy and immunoglobulin A vasculitis in Koreans. Genes Genomics 2021;43:1049-57. [PMID: 34146253 DOI: 10.1007/s13258-021-01120-0] [Reference Citation Analysis]
116 Szarvas N, Szilágyi Á, Csuka D, Takács B, Rusai K, Müller T, Arbeiter K, Réti M, Haris Á, Wagner L, Török S, Kelen K, Szabó AJ, Reusz GS, Morgan BP, Prohászka Z. Genetic analysis and functional characterization of novel mutations in a series of patients with atypical hemolytic uremic syndrome. Molecular Immunology 2016;71:10-22. [DOI: 10.1016/j.molimm.2016.01.003] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
117 Garcia-cazorla À, Mochel F, Lamari F, Saudubray J. The clinical spectrum of inherited diseases involved in the synthesis and remodeling of complex lipids. A tentative overview. J Inherit Metab Dis 2015;38:19-40. [DOI: 10.1007/s10545-014-9776-6] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 4.4] [Reference Citation Analysis]
118 Åkesson A, Zetterberg E, Klintman J. At the Cross Section of Thrombotic Microangiopathy and Atypical Hemolytic Uremic Syndrome: A Narrative Review of Differential Diagnostics and a Problematization of Nomenclature: At the Cross Section of TMA and aHUS. Ther Apher Dial 2017;21:304-19. [DOI: 10.1111/1744-9987.12535] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
119 Galbusera M, Noris M, Gastoldi S, Bresin E, Mele C, Breno M, Cuccarolo P, Alberti M, Valoti E, Piras R, Donadelli R, Vivarelli M, Murer L, Pecoraro C, Ferrari E, Perna A, Benigni A, Portalupi V, Remuzzi G. An Ex Vivo Test of Complement Activation on Endothelium for Individualized Eculizumab Therapy in Hemolytic Uremic Syndrome. Am J Kidney Dis 2019;74:56-72. [PMID: 30851964 DOI: 10.1053/j.ajkd.2018.11.012] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 8.7] [Reference Citation Analysis]
120 Vilarinho S, Sari S, Mazzacuva F, Bilgüvar K, Esendagli-Yilmaz G, Jain D, Akyol G, Dalgiç B, Günel M, Clayton PT, Lifton RP. ACOX2 deficiency: A disorder of bile acid synthesis with transaminase elevation, liver fibrosis, ataxia, and cognitive impairment. Proc Natl Acad Sci U S A 2016;113:11289-93. [PMID: 27647924 DOI: 10.1073/pnas.1613228113] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 7.0] [Reference Citation Analysis]
121 Raina R, Krishnappa V, Blaha T, Kann T, Hein W, Burke L, Bagga A. Atypical Hemolytic-Uremic Syndrome: An Update on Pathophysiology, Diagnosis, and Treatment. Ther Apher Dial 2019;23:4-21. [PMID: 30294946 DOI: 10.1111/1744-9987.12763] [Cited by in Crossref: 29] [Cited by in F6Publishing: 20] [Article Influence: 7.3] [Reference Citation Analysis]
122 Durkan AM, Kim S, Craig J, Elliott E. The long-term outcomes of atypical haemolytic uraemic syndrome: a national surveillance study. Arch Dis Child 2016;101:387-91. [PMID: 26729748 DOI: 10.1136/archdischild-2015-309471] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
123 Devuyst O, Knoers NV, Remuzzi G, Schaefer F; Board of the Working Group for Inherited Kidney Diseases of the European Renal Association and European Dialysis and Transplant Association. Rare inherited kidney diseases: challenges, opportunities, and perspectives. Lancet 2014;383:1844-59. [PMID: 24856029 DOI: 10.1016/S0140-6736(14)60659-0] [Cited by in Crossref: 123] [Cited by in F6Publishing: 63] [Article Influence: 15.4] [Reference Citation Analysis]
124 Fox LC, Cohney SJ, Kausman JY, Shortt J, Hughes PD, Wood EM, Isbel NM, de Malmanche T, Durkan A, Hissaria P, Blombery P, Barbour TD. Consensus opinion on diagnosis and management of thrombotic microangiopathy in Australia and New Zealand: Thrombotic microangiopathy in Aust/NZ. Nephrology 2018;23:507-17. [DOI: 10.1111/nep.13234] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
125 Li J, Song Y, Zhang Y, Li H, Tian M, Li D, Zhang S, Cao G, Liu C. A novel compound heterozygous mutation in DGKE in a Chinese patient causes atypical hemolytic uremic syndrome. Hematology 2020;25:101-7. [PMID: 32091318 DOI: 10.1080/16078454.2020.1731969] [Reference Citation Analysis]
126 Anders R, Grohmann M, Lindner TH, Bergmann C, Halbritter J. [Hemolytic kidney failure and transient ischemic attack in a 32-year-old female]. Internist (Berl) 2016;57:1022-8. [PMID: 27357251 DOI: 10.1007/s00108-016-0092-0] [Reference Citation Analysis]
127 Brocklebank V, Wood KM, Kavanagh D. Thrombotic Microangiopathy and the Kidney. Clin J Am Soc Nephrol. 2018;13:300-317. [PMID: 29042465 DOI: 10.2215/cjn.00620117] [Cited by in Crossref: 103] [Cited by in F6Publishing: 57] [Article Influence: 20.6] [Reference Citation Analysis]
128 Alge JL, Wenderfer SE, Hicks J, Bekheirnia MR, Schady DA, Kain JS, Braun MC. Hemolytic uremic syndrome as the presenting manifestation of WT1 mutation and Denys-Drash syndrome: a case report. BMC Nephrol 2017;18:243. [PMID: 28720077 DOI: 10.1186/s12882-017-0643-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
129 Sheerin NS, Glover E. Haemolytic uremic syndrome: diagnosis and management. F1000Res 2019;8:F1000 Faculty Rev-1690. [PMID: 31598213 DOI: 10.12688/f1000research.19957.1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
130 Kaplan BS, Ruebner RL, Spinale JM, Copelovitch L. Current treatment of atypical hemolytic uremic syndrome. Intractable Rare Dis Res. 2014;3:34-45. [PMID: 25343125 DOI: 10.5582/irdr.2014.01001] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 4.6] [Reference Citation Analysis]
131 Westra D, Volokhina EB, van der Molen RG, van der Velden TJ, Jeronimus-Klaasen A, Goertz J, Gracchi V, Dorresteijn EM, Bouts AH, Keijzer-Veen MG, van Wijk JA, Bakker JA, Roos A, van den Heuvel LP, van de Kar NC. Serological and genetic complement alterations in infection-induced and complement-mediated hemolytic uremic syndrome. Pediatr Nephrol 2017;32:297-309. [PMID: 27718086 DOI: 10.1007/s00467-016-3496-0] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 4.3] [Reference Citation Analysis]
132 Perkins SJ. Genetic and Protein Structural Evaluation of Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy. Adv Chronic Kidney Dis 2020;27:120-127.e4. [PMID: 32553244 DOI: 10.1053/j.ackd.2020.03.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
133 Challis RC, Ring T, Xu Y, Wong EK, Flossmann O, Roberts IS, Ahmed S, Wetherall M, Salkus G, Brocklebank V, Fester J, Strain L, Wilson V, Wood KM, Marchbank KJ, Santibanez-Koref M, Goodship TH, Kavanagh D. Thrombotic Microangiopathy in Inverted Formin 2-Mediated Renal Disease. J Am Soc Nephrol 2017;28:1084-91. [PMID: 27974406 DOI: 10.1681/ASN.2015101189] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
134 Bernabéu-Herrero ME, Jiménez-Alcázar M, Anter J, Pinto S, Sánchez Chinchilla D, Garrido S, López-Trascasa M, Rodríguez de Córdoba S, Sánchez-Corral P. Complement factor H, FHR-3 and FHR-1 variants associate in an extended haplotype conferring increased risk of atypical hemolytic uremic syndrome. Mol Immunol 2015;67:276-86. [PMID: 26163426 DOI: 10.1016/j.molimm.2015.06.021] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 4.4] [Reference Citation Analysis]
135 Alabdulqader M, Alfakeeh K. A patient with a homozygous diacylglycerol kinase epsilon (DGKE) gene mutation with atypical haemolytic uraemic syndrome and low C3 responded well to eculizumab: a case report. BMC Nephrol 2021;22:140. [PMID: 33879077 DOI: 10.1186/s12882-021-02352-8] [Reference Citation Analysis]
136 Noris M, Remuzzi G. Genetics of Immune-Mediated Glomerular Diseases: Focus on Complement. Seminars in Nephrology 2017;37:447-63. [DOI: 10.1016/j.semnephrol.2017.05.018] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
137 Zhu J, Chaki M, Lu D, Ren C, Wang SS, Rauhauser A, Li B, Zimmerman S, Jun B, Du Y, Vadnagara K, Wang H, Elhadi S, Quigg RJ, Topham MK, Mohan C, Ozaltin F, Zhou XJ, Marciano DK, Bazan NG, Attanasio M. Loss of diacylglycerol kinase epsilon in mice causes endothelial distress and impairs glomerular Cox-2 and PGE2 production. Am J Physiol Renal Physiol 2016;310:F895-908. [PMID: 26887830 DOI: 10.1152/ajprenal.00431.2015] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
138 Webb TN, Griffiths H, Miyashita Y, Bhatt R, Jaffe R, Moritz M, Hofer J, Swiatecka-Urban A. Atypical Hemolytic Uremic Syndrome and Chronic Ulcerative Colitis Treated with Eculizumab. Int J Med Pharm Case Reports 2015;4:105-12. [PMID: 27135055 DOI: 10.9734/IJMPCR/2015/18771] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
139 Kavanagh D, Smith-Jackson K. Eculizumab in children with hemolytic uremic syndrome. Kidney Int 2016;89:537-8. [PMID: 26880449 DOI: 10.1016/j.kint.2015.12.039] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
140 Wong EK, Kavanagh D. Anticomplement C5 therapy with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Transl Res 2015;165:306-20. [PMID: 25468487 DOI: 10.1016/j.trsl.2014.10.010] [Cited by in Crossref: 58] [Cited by in F6Publishing: 45] [Article Influence: 7.3] [Reference Citation Analysis]
141 McMahon BA, Moran RA, Sperati CJ, Bagnasco S, Novick T, Atta MG. Renal Thrombotic Microangiopathy, Podocytopathy, and Chylous Ascites: A Hard-Nosed Diagnosis. Am J Med 2016;129:e227-31. [PMID: 27154780 DOI: 10.1016/j.amjmed.2016.04.011] [Reference Citation Analysis]
142 Ballermann BJ, Nyström J, Haraldsson B. The Glomerular Endothelium Restricts Albumin Filtration. Front Med (Lausanne) 2021;8:766689. [PMID: 34912827 DOI: 10.3389/fmed.2021.766689] [Reference Citation Analysis]
143 Jennings W, Doshi S, D'Souza K, Epand RM. Molecular properties of diacylglycerol kinase-epsilon in relation to function. Chem Phys Lipids 2015;192:100-8. [PMID: 26134136 DOI: 10.1016/j.chemphyslip.2015.06.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
144 Connaughton DM, Hildebrandt F. Personalized medicine in chronic kidney disease by detection of monogenic mutations. Nephrol Dial Transplant 2020;35:390-7. [PMID: 30809662 DOI: 10.1093/ndt/gfz028] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 9.0] [Reference Citation Analysis]
145 Kottke-marchant K. Diagnostic approach to microangiopathic hemolytic disorders. Int J Lab Hem 2017;39:69-75. [DOI: 10.1111/ijlh.12671] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
146 Caeiro Alves F, Aguiar R, Pessegueiro P, Pires C. Thrombotic microangiopathy associated with Mycoplasma pneumoniae infection. BMJ Case Rep 2018;2018:bcr-2017-222582. [PMID: 29550758 DOI: 10.1136/bcr-2017-222582] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
147 Sampson MG. Actualizing the Benefits of Genomic Discovery in Pediatric Nephrology. J Pediatr Genet 2016;5:69-75. [PMID: 27617144 DOI: 10.1055/s-0035-1557113] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
148 Vivante A, Hildebrandt F. Exploring the genetic basis of early-onset chronic kidney disease. Nat Rev Nephrol 2016;12:133-46. [PMID: 26750453 DOI: 10.1038/nrneph.2015.205] [Cited by in Crossref: 163] [Cited by in F6Publishing: 129] [Article Influence: 27.2] [Reference Citation Analysis]
149 Miyata T, Uchida Y, Yoshida Y, Kato H, Matsumoto M, Kokame K, Fujimura Y, Nangaku M. No association between dysplasminogenemia with p.Ala620Thr mutation and atypical hemolytic uremic syndrome. Int J Hematol 2016;104:223-7. [PMID: 27194432 DOI: 10.1007/s12185-016-2021-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
150 Rathbone J, Kaltenthaler E, Richards A, Tappenden P, Bessey A, Cantrell A. A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS). BMJ Open. 2013;3:e003573. [PMID: 24189082 DOI: 10.1136/bmjopen-2013-003573] [Cited by in Crossref: 59] [Cited by in F6Publishing: 54] [Article Influence: 6.6] [Reference Citation Analysis]
151 Moroi AJ, Zwifelhofer NM, Riese MJ, Newman DK, Newman PJ. Diacylglycerol kinase ζ is a negative regulator of GPVI-mediated platelet activation. Blood Adv 2019;3:1154-66. [PMID: 30967391 DOI: 10.1182/bloodadvances.2018026328] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
152 Licht C, Greenbaum LA, Muus P, Babu S, Bedrosian CL, Cohen DJ, Delmas Y, Douglas K, Furman RR, Gaber OA, Goodship T, Herthelius M, Hourmant M, Legendre CM, Remuzzi G, Sheerin N, Trivelli A, Loirat C. Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int. 2015;87:1061-1073. [PMID: 25651368 DOI: 10.1038/ki.2014.423] [Cited by in Crossref: 234] [Cited by in F6Publishing: 194] [Article Influence: 33.4] [Reference Citation Analysis]
153 Ávila A, Vizcaíno B, Molina P, Gavela E, Perez-Ebri M, Pallardó L. Remission of aHUS neurological damage with eculizumab. Clin Kidney J 2015;8:232-6. [PMID: 25815183 DOI: 10.1093/ckj/sfu144] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
154 Baines AC, Brodsky RA. Complementopathies. Blood Rev 2017;31:213-23. [PMID: 28215731 DOI: 10.1016/j.blre.2017.02.003] [Cited by in Crossref: 54] [Cited by in F6Publishing: 46] [Article Influence: 10.8] [Reference Citation Analysis]
155 Tsai HM, Kuo E. Eculizumab therapy leads to rapid resolution of thrombocytopenia in atypical hemolytic uremic syndrome. Adv Hematol 2014;2014:295323. [PMID: 25400666 DOI: 10.1155/2014/295323] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
156 Timmermans SAMEG, van Paassen P. The Syndromes of Thrombotic Microangiopathy: A Critical Appraisal on Complement Dysregulation. J Clin Med 2021;10:3034. [PMID: 34300201 DOI: 10.3390/jcm10143034] [Reference Citation Analysis]
157 Ars E, Torra R. Rare diseases, rare presentations: recognizing atypical inherited kidney disease phenotypes in the age of genomics. Clin Kidney J 2017;10:586-93. [PMID: 28980669 DOI: 10.1093/ckj/sfx051] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
158 Peyvandi F, Rossio R, Ferrari B, Lotta LA, Pontiggia S, Ghiringhelli Borsa N, Pizzuti M, Donadelli R, Piras R, Cugno M, Noris M. Thrombotic microangiopathy without renal involvement: two novel mutations in complement-regulator genes. J Thromb Haemost 2016;14:340-5. [PMID: 26613809 DOI: 10.1111/jth.13210] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
159 Nester CM, Barbour T, de Cordoba SR, Dragon-Durey MA, Fremeaux-Bacchi V, Goodship TH, Kavanagh D, Noris M, Pickering M, Sanchez-Corral P. Atypical aHUS: State of the art. Mol Immunol. 2015;67:31-42. [PMID: 25843230 DOI: 10.1016/j.molimm.2015.03.246] [Cited by in Crossref: 162] [Cited by in F6Publishing: 136] [Article Influence: 23.1] [Reference Citation Analysis]
160 Campistol JM, Arias M, Ariceta G, Blasco M, Espinosa L, Espinosa M, Grinyó JM, Macía M, Mendizábal S, Praga M, Román E, Torra R, Valdés F, Vilalta R, Rodríguez de Córdoba S. An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document. Nefrologia 2015;35:421-47. [PMID: 26456110 DOI: 10.1016/j.nefro.2015.07.005] [Cited by in Crossref: 88] [Cited by in F6Publishing: 63] [Article Influence: 12.6] [Reference Citation Analysis]
161 Lemaire M, Noone D, Lapeyraque AL, Licht C, Frémeaux-Bacchi V. Inherited Kidney Complement Diseases. Clin J Am Soc Nephrol 2021;16:942-56. [PMID: 33536243 DOI: 10.2215/CJN.11830720] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
162 Frémeaux-Bacchi V. [Pathophysiology of atypical hemolytic uremic syndrome. Ten years of progress, from laboratory to patient]. Biol Aujourdhui 2013;207:231-40. [PMID: 24594571 DOI: 10.1051/jbio/2013027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
163 Campistol JM, Arias M, Ariceta G, Blasco M, Espinosa L, Espinosa M, Grinyó JM, Macía M, Mendizábal S, Praga M, Román E, Torra R, Valdés F, Vilalta R, Rodríguez de Córdoba S. An update for atypical haemolytic uraemic syndrome: Diagnosis and treatment. A consensus document. Nefrología (English Edition) 2015;35:421-47. [DOI: 10.1016/j.nefroe.2015.11.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 1.1] [Reference Citation Analysis]
164 MacArthur DG, Manolio TA, Dimmock DP, Rehm HL, Shendure J, Abecasis GR, Adams DR, Altman RB, Antonarakis SE, Ashley EA, Barrett JC, Biesecker LG, Conrad DF, Cooper GM, Cox NJ, Daly MJ, Gerstein MB, Goldstein DB, Hirschhorn JN, Leal SM, Pennacchio LA, Stamatoyannopoulos JA, Sunyaev SR, Valle D, Voight BF, Winckler W, Gunter C. Guidelines for investigating causality of sequence variants in human disease. Nature 2014;508:469-76. [PMID: 24759409 DOI: 10.1038/nature13127] [Cited by in Crossref: 871] [Cited by in F6Publishing: 749] [Article Influence: 108.9] [Reference Citation Analysis]
165 Jin SC, Homsy J, Zaidi S, Lu Q, Morton S, DePalma SR, Zeng X, Qi H, Chang W, Sierant MC, Hung WC, Haider S, Zhang J, Knight J, Bjornson RD, Castaldi C, Tikhonoa IR, Bilguvar K, Mane SM, Sanders SJ, Mital S, Russell MW, Gaynor JW, Deanfield J, Giardini A, Porter GA Jr, Srivastava D, Lo CW, Shen Y, Watkins WS, Yandell M, Yost HJ, Tristani-Firouzi M, Newburger JW, Roberts AE, Kim R, Zhao H, Kaltman JR, Goldmuntz E, Chung WK, Seidman JG, Gelb BD, Seidman CE, Lifton RP, Brueckner M. Contribution of rare inherited and de novo variants in 2,871 congenital heart disease probands. Nat Genet 2017;49:1593-601. [PMID: 28991257 DOI: 10.1038/ng.3970] [Cited by in Crossref: 327] [Cited by in F6Publishing: 263] [Article Influence: 65.4] [Reference Citation Analysis]
166 Davin JC, van de Kar NC. Advances and challenges in the management of complement-mediated thrombotic microangiopathies. Ther Adv Hematol 2015;6:171-85. [PMID: 26288712 DOI: 10.1177/2040620715577613] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
167 Fan X, Kremer Hovinga JA, Shirotani-ikejima H, Eura Y, Hirai H, Honda S, Kokame K, Taleghani MM, von Krogh A, Yoshida Y, Fujimura Y, Lämmle B, Miyata T. Genetic variations in complement factors in patients with congenital thrombotic thrombocytopenic purpura with renal insufficiency. Int J Hematol 2016;103:283-91. [DOI: 10.1007/s12185-015-1933-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
168 Gavriilaki E, Anagnostopoulos A, Mastellos DC. Complement in Thrombotic Microangiopathies: Unraveling Ariadne's Thread Into the Labyrinth of Complement Therapeutics. Front Immunol 2019;10:337. [PMID: 30891033 DOI: 10.3389/fimmu.2019.00337] [Cited by in Crossref: 35] [Cited by in F6Publishing: 27] [Article Influence: 11.7] [Reference Citation Analysis]
169 Picard C, Burtey S, Bornet C, Curti C, Montana M, Vanelle P. Pathophysiology and treatment of typical and atypical hemolytic uremic syndrome. Pathologie Biologie 2015;63:136-43. [DOI: 10.1016/j.patbio.2015.03.001] [Cited by in Crossref: 30] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
170 Gleeson PJ, Wilson V, Cox TE, Sharma SD, Smith-Jackson K, Strain L, Lappin D, McHale T, Kavanagh D, Goodship TH. Chromosomal rearrangement-A rare cause of complement factor I associated atypical haemolytic uraemic syndrome. Immunobiology 2016;221:1124-30. [PMID: 27268256 DOI: 10.1016/j.imbio.2016.05.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
171 Michael M, Turner N, Elenberg E, Shaffer LG, Teruya J, Arar M, Hui SK, Smith RJ, Moake J. Deficiency of complement factor H-related proteins and autoantibody-positive hemolytic uremic syndrome in an infant with combined partial deficiencies and autoantibodies to complement factor H and ADAMTS13. Clin Kidney J 2018;11:791-6. [PMID: 30524124 DOI: 10.1093/ckj/sfy010] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
172 Noris M, Mele C, Remuzzi G. Podocyte dysfunction in atypical haemolytic uraemic syndrome. Nat Rev Nephrol 2015;11:245-52. [PMID: 25599621 DOI: 10.1038/nrneph.2014.250] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 4.4] [Reference Citation Analysis]
173 Loirat C, Fakhouri F, Ariceta G, Besbas N, Bitzan M, Bjerre A, Coppo R, Emma F, Johnson S, Karpman D. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol. 2016;31:15-39. [PMID: 25859752 DOI: 10.1007/s00467-015-3076-8] [Cited by in Crossref: 272] [Cited by in F6Publishing: 210] [Article Influence: 38.9] [Reference Citation Analysis]
174 Alexander MP, Fervenza FC, De Vriese AS, Smith RJH, Nasr SH, Cornell LD, Herrera Hernandez LP, Zhang Y, Sethi S. C3 glomerulonephritis and autoimmune disease: more than a fortuitous association? J Nephrol 2016;29:203-9. [DOI: 10.1007/s40620-015-0218-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
175 Meri S. Complement activation in diseases presenting with thrombotic microangiopathy. Eur J Intern Med 2013;24:496-502. [PMID: 23743117 DOI: 10.1016/j.ejim.2013.05.009] [Cited by in Crossref: 58] [Cited by in F6Publishing: 51] [Article Influence: 6.4] [Reference Citation Analysis]
176 Hoenecke J, Hartmann H, Melk A. Arterial hypertension in children with hemolytic uremic syndrome after kidney transplantation. Pediatr Transplant 2015;19:504-9. [PMID: 26073101 DOI: 10.1111/petr.12533] [Reference Citation Analysis]
177 Ranawaka R, Dayasiri K, Gamage M. Combined liver and kidney transplantation in children and long-term outcome. World J Transplant 2020; 10(10): 283-290 [PMID: 33134116 DOI: 10.5500/wjt.v10.i10.283] [Cited by in CrossRef: 2] [Article Influence: 1.0] [Reference Citation Analysis]
178 Roumenina LT, Rayes J, Frimat M, Fremeaux-Bacchi V. Endothelial cells: source, barrier, and target of defensive mediators. Immunol Rev 2016;274:307-29. [PMID: 27782324 DOI: 10.1111/imr.12479] [Cited by in Crossref: 54] [Cited by in F6Publishing: 56] [Article Influence: 10.8] [Reference Citation Analysis]
179 Nakano T, Goto K. Diacylglycerol Kinase ε in Adipose Tissues: A Crosstalk Between Signal Transduction and Energy Metabolism. Front Physiol 2022;13:815085. [DOI: 10.3389/fphys.2022.815085] [Reference Citation Analysis]
180 Pollack S, Eisenstein I, Mory A, Paperna T, Ofir A, Baris-Feldman H, Weiss K, Veszeli N, Csuka D, Shemer R, Glaser F, Prohászka Z, Magen D. A Novel Homozygous In-Frame Deletion in Complement Factor 3 Underlies Early-Onset Autosomal Recessive Atypical Hemolytic Uremic Syndrome - Case Report. Front Immunol 2021;12:608604. [PMID: 34248927 DOI: 10.3389/fimmu.2021.608604] [Reference Citation Analysis]
181 Øzbay LA. Eculizumab treatment of thrombotic microangiopathy in a patient with ulcerative colitis. Clin J Gastroenterol 2020;13:344-8. [PMID: 31612381 DOI: 10.1007/s12328-019-01052-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
182 Kościelska-Kasprzak K, Bartoszek D, Myszka M, Zabińska M, Klinger M. The complement cascade and renal disease. Arch Immunol Ther Exp (Warsz) 2014;62:47-57. [PMID: 24030732 DOI: 10.1007/s00005-013-0254-x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 4.4] [Reference Citation Analysis]
183 Fakhouri F, Zuber J, Frémeaux-Bacchi V, Loirat C. Haemolytic uraemic syndrome. Lancet 2017;390:681-96. [PMID: 28242109 DOI: 10.1016/S0140-6736(17)30062-4] [Cited by in Crossref: 202] [Cited by in F6Publishing: 108] [Article Influence: 40.4] [Reference Citation Analysis]
184 Noris M, Galbusera M, Gastoldi S, Macor P, Banterla F, Bresin E, Tripodo C, Bettoni S, Donadelli R, Valoti E, Tedesco F, Amore A, Coppo R, Ruggenenti P, Gotti E, Remuzzi G. Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. Blood. 2014;124:1715-1726. [PMID: 25037630 DOI: 10.1182/blood-2014-02-558296] [Cited by in Crossref: 189] [Cited by in F6Publishing: 171] [Article Influence: 23.6] [Reference Citation Analysis]
185 Zipfel PF, Wiech T, Stea ED, Skerka C. CFHR Gene Variations Provide Insights in the Pathogenesis of the Kidney Diseases Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy. J Am Soc Nephrol 2020;31:241-56. [PMID: 31980588 DOI: 10.1681/ASN.2019050515] [Cited by in Crossref: 20] [Cited by in F6Publishing: 11] [Article Influence: 10.0] [Reference Citation Analysis]
186 Sperati CJ, Moliterno AR. Thrombotic Microangiopathy. Hematology/Oncology Clinics of North America 2015;29:541-59. [DOI: 10.1016/j.hoc.2015.02.002] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
187 Noone DG, Riedl M, Licht C. The role of von Willebrand factor in thrombotic microangiopathy. Pediatr Nephrol 2018;33:1297-307. [DOI: 10.1007/s00467-017-3744-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
188 Schwartz J, Padmanabhan A, Aqui N, Balogun RA, Connelly-Smith L, Delaney M, Dunbar NM, Witt V, Wu Y, Shaz BH. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue. J Clin Apher. 2016;31:149-162. [PMID: 27322218 DOI: 10.1002/jca.21470] [Cited by in Crossref: 168] [Cited by in F6Publishing: 216] [Article Influence: 33.6] [Reference Citation Analysis]
189 Thakur R, Naik A, Panda A, Raghu P. Regulation of Membrane Turnover by Phosphatidic Acid: Cellular Functions and Disease Implications. Front Cell Dev Biol 2019;7:83. [PMID: 31231646 DOI: 10.3389/fcell.2019.00083] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
190 Berger BE. The Alternative Pathway of Complement and the Evolving Clinical-Pathophysiological Spectrum of Atypical Hemolytic Uremic Syndrome. Am J Med Sci 2016;352:177-90. [PMID: 27524217 DOI: 10.1016/j.amjms.2016.05.003] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
191 Karpman D, Loos S, Tati R, Arvidsson I. Haemolytic uraemic syndrome. J Intern Med 2017;281:123-48. [DOI: 10.1111/joim.12546] [Cited by in Crossref: 72] [Cited by in F6Publishing: 65] [Article Influence: 12.0] [Reference Citation Analysis]
192 Liu D, Ding Q, Dai DF, Padhy B, Nayak MK, Li C, Purvis M, Jin H, Shu C, Chauhan AK, Huang CL, Attanasio M. Loss of diacylglycerol kinase ε causes thrombotic microangiopathy by impairing endothelial VEGFA signaling. JCI Insight 2021;6:146959. [PMID: 33986189 DOI: 10.1172/jci.insight.146959] [Reference Citation Analysis]
193 Mele C, Lemaire M, Iatropoulos P, Piras R, Bresin E, Bettoni S, Bick D, Helbling D, Veith R, Valoti E, Donadelli R, Murer L, Neunhäuserer M, Breno M, Frémeaux-Bacchi V, Lifton R, Remuzzi G, Noris M. Characterization of a New DGKE Intronic Mutation in Genetically Unsolved Cases of Familial Atypical Hemolytic Uremic Syndrome. Clin J Am Soc Nephrol 2015;10:1011-9. [PMID: 25854283 DOI: 10.2215/CJN.08520814] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 4.6] [Reference Citation Analysis]
194 Zhang K, Lu Y, Harley KT, Tran MH. Atypical Hemolytic Uremic Syndrome: A Brief Review. Hematol Rep 2017;9:7053. [PMID: 28626544 DOI: 10.4081/hr.2017.7053] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 5.2] [Reference Citation Analysis]
195 Loirat C, Frémeaux-Bacchi V. Anti-factor H autoantibody-associated hemolytic uremic syndrome: the earlier diagnosed and treated, the better. Kidney Int 2014;85:1019-22. [PMID: 24786877 DOI: 10.1038/ki.2013.447] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
196 Zimbudzi E. Overcoming technical challenges when treating atypical hemolytic uremic syndrome with therapeutic plasma exchange. Int J Nephrol Renovasc Dis 2013;6:245-8. [PMID: 24277990 DOI: 10.2147/IJNRD.S53074] [Reference Citation Analysis]
197 Lamari F, Mochel F, Saudubray J. An overview of inborn errors of complex lipid biosynthesis and remodelling. J Inherit Metab Dis 2015;38:3-18. [DOI: 10.1007/s10545-014-9764-x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 5.1] [Reference Citation Analysis]
198 Mallett A, Corney C, McCarthy H, Alexander SI, Healy H. Genomics in the renal clinic - translating nephrogenetics for clinical practice. Hum Genomics 2015;9:13. [PMID: 26104748 DOI: 10.1186/s40246-015-0035-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
199 de Holanda MI, Gomes CP, Araujo SA, Wanderley DC, Eick RG, Dantas GC, Tino MKDS, Pesquero JB, Palma LMP. Diacylglycerol kinase epsilon nephropathy: late diagnosis and therapeutic implications. Clin Kidney J 2019;12:641-4. [PMID: 31583090 DOI: 10.1093/ckj/sfz043] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
200 Anastaze Stelle K, Gonzalez E, Wilhelm-Bals A, Michelet PR, Korff CM, Parvex P. Successful treatment of neonatal atypical hemolytic uremic syndrome with C5 monoclonal antibody. Arch Pediatr 2016;23:283-6. [PMID: 26775886 DOI: 10.1016/j.arcped.2015.11.020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
201 Kato H, Nangaku M, Hataya H, Sawai T, Ashida A, Fujimaru R, Hidaka Y, Kaname S, Maruyama S, Yasuda T, Yoshida Y, Ito S, Hattori M, Miyakawa Y, Fujimura Y, Okada H, Kagami S; Joint Committee for the Revision of Clinical Guides of Atypical Hemolytic Uremic Syndrome in Japan. Clinical guides for atypical hemolytic uremic syndrome in Japan. Clin Exp Nephrol 2016;20:536-43. [PMID: 27422619 DOI: 10.1007/s10157-016-1276-6] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 4.4] [Reference Citation Analysis]
202 Husain D, Barron B, Barron AG, Sandokji I, Marsenic O, Warejko JK. Atypical hemolytic uremic syndrome due to DGKE mutation and response to eculizumab: lessons for the clinical nephrologist. J Nephrol 2021;34:1331-5. [PMID: 33751496 DOI: 10.1007/s40620-020-00925-8] [Reference Citation Analysis]
203 Vester U, Mache CJ. Pharmacological treatment of atypical hemolytic-uremic syndrome. Expert Opinion on Orphan Drugs 2014;2:123-35. [DOI: 10.1517/21678707.2014.872029] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
204 Mallett A, Patel C, Maier B, McGaughran J, Gabbett M, Takasato M, Cameron A, Trnka P, Alexander SI, Rangan G, Tchan MC, Caruana G, John G, Quinlan C, McCarthy HJ, Hyland V, Hoy WE, Wolvetang E, Taft R, Simons C, Healy H, Little M. A protocol for the identification and validation of novel genetic causes of kidney disease. BMC Nephrol 2015;16:152. [PMID: 26374634 DOI: 10.1186/s12882-015-0148-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
205 Duran D, Jin SC, DeSpenza T Jr, Nelson-Williams C, Cogal AG, Abrash EW, Harris PC, Lieske JC, Shimshak SJ, Mane S, Bilguvar K, DiLuna ML, Günel M, Lifton RP, Kahle KT. Digenic mutations of human OCRL paralogs in Dent's disease type 2 associated with Chiari I malformation. Hum Genome Var 2016;3:16042. [PMID: 28018608 DOI: 10.1038/hgv.2016.42] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
206 Wong EK, Goodship TH, Kavanagh D. Complement therapy in atypical haemolytic uraemic syndrome (aHUS). Mol Immunol 2013;56:199-212. [PMID: 23810412 DOI: 10.1016/j.molimm.2013.05.224] [Cited by in Crossref: 60] [Cited by in F6Publishing: 54] [Article Influence: 6.7] [Reference Citation Analysis]
207 Schaefer F, Ardissino G, Ariceta G, Fakhouri F, Scully M, Isbel N, Lommelé Å, Kupelian V, Gasteyger C, Greenbaum LA, Johnson S, Ogawa M, Licht C, Vande Walle J, Frémeaux-Bacchi V; Global aHUS Registry. Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype and outcome. Kidney Int 2018;94:408-18. [PMID: 29907460 DOI: 10.1016/j.kint.2018.02.029] [Cited by in Crossref: 51] [Cited by in F6Publishing: 40] [Article Influence: 12.8] [Reference Citation Analysis]
208 Saito D, Watanabe E, Ashida A, Kato H, Yoshida Y, Nangaku M, Ohtsuka Y, Miyata T, Hattori N, Oda S. Atypical Hemolytic Uremic Syndrome With the p.Ile1157Thr C3 Mutation Successfully Treated With Plasma Exchange and Eculizumab: A Case Report. Crit Care Explor 2019;1:e0008. [PMID: 32166254 DOI: 10.1097/CCE.0000000000000008] [Reference Citation Analysis]
209 Scholl UI, Stölting G, Nelson-Williams C, Vichot AA, Choi M, Loring E, Prasad ML, Goh G, Carling T, Juhlin CC, Quack I, Rump LC, Thiel A, Lande M, Frazier BG, Rasoulpour M, Bowlin DL, Sethna CB, Trachtman H, Fahlke C, Lifton RP. Recurrent gain of function mutation in calcium channel CACNA1H causes early-onset hypertension with primary aldosteronism. Elife 2015;4:e06315. [PMID: 25907736 DOI: 10.7554/eLife.06315] [Cited by in Crossref: 173] [Cited by in F6Publishing: 86] [Article Influence: 24.7] [Reference Citation Analysis]
210 Cody EM, Dixon BP. Hemolytic Uremic Syndrome. Pediatric Clinics of North America 2019;66:235-46. [DOI: 10.1016/j.pcl.2018.09.011] [Cited by in Crossref: 36] [Cited by in F6Publishing: 24] [Article Influence: 12.0] [Reference Citation Analysis]
211 Ito N, Hataya H, Saida K, Amano Y, Hidaka Y, Motoyoshi Y, Ohta T, Yoshida Y, Terano C, Iwasa T, Kubota W, Takada H, Hara T, Fujimura Y, Ito S. Efficacy and safety of eculizumab in childhood atypical hemolytic uremic syndrome in Japan. Clin Exp Nephrol 2016;20:265-72. [DOI: 10.1007/s10157-015-1142-y] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
212 Wong EKS, Kavanagh D. Diseases of complement dysregulation-an overview. Semin Immunopathol 2018;40:49-64. [PMID: 29327071 DOI: 10.1007/s00281-017-0663-8] [Cited by in Crossref: 45] [Cited by in F6Publishing: 38] [Article Influence: 11.3] [Reference Citation Analysis]
213 Grisaru S. Management of hemolytic-uremic syndrome in children. Int J Nephrol Renovasc Dis 2014;7:231-9. [PMID: 24966691 DOI: 10.2147/IJNRD.S41837] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
214 Fakhouri F, Frémeaux-Bacchi V, Loirat C. Atypical hemolytic uremic syndrome: from the rediscovery of complement to targeted therapy. Eur J Intern Med 2013;24:492-5. [PMID: 23756030 DOI: 10.1016/j.ejim.2013.05.008] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
215 Abbas F, El Kossi M, Kim JJ, Sharma A, Halawa A. Thrombotic microangiopathy after renal transplantation: Current insights in de novo and recurrent disease. World J Transplantation 2018; 8(5): 122-141 [PMID: 30211021 DOI: 10.5500/wjt.v8.i5.122] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 8] [Article Influence: 4.8] [Reference Citation Analysis]
216 Mallett AJ, McCarthy HJ, Ho G, Holman K, Farnsworth E, Patel C, Fletcher JT, Mallawaarachchi A, Quinlan C, Bennetts B, Alexander SI. Massively parallel sequencing and targeted exomes in familial kidney disease can diagnose underlying genetic disorders. Kidney Int 2017;92:1493-506. [PMID: 28844315 DOI: 10.1016/j.kint.2017.06.013] [Cited by in Crossref: 44] [Cited by in F6Publishing: 32] [Article Influence: 8.8] [Reference Citation Analysis]
217 Fakhouri F, Frémeaux-Bacchi V. Thrombotic microangiopathy in aHUS and beyond: clinical clues from complement genetics. Nat Rev Nephrol 2021;17:543-53. [PMID: 33953366 DOI: 10.1038/s41581-021-00424-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
218 Franchini M. Atypical hemolytic uremic syndrome: from diagnosis to treatment. Clinical Chemistry and Laboratory Medicine (CCLM) 2015;53. [DOI: 10.1515/cclm-2015-0024] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
219 Jokiranta TS. HUS and atypical HUS. Blood. 2017;129:2847-2856. [PMID: 28416508 DOI: 10.1182/blood-2016-11-709865] [Cited by in Crossref: 124] [Cited by in F6Publishing: 101] [Article Influence: 24.8] [Reference Citation Analysis]
220 Gholizad-Kolveiri S, Hooman N, Alizadeh R, Hoseini R, Otukesh H, Talebi S, Akouchekian M. Whole exome sequencing revealed a novel homozygous variant in the DGKE catalytic domain: a case report of familial hemolytic uremic syndrome. BMC Med Genet 2020;21:169. [PMID: 32838746 DOI: 10.1186/s12881-020-01097-9] [Reference Citation Analysis]
221 Ollero M, Sahali D. Inhibition of the VEGF signalling pathway and glomerular disorders. Nephrol Dial Transplant 2015;30:1449-55. [PMID: 25480873 DOI: 10.1093/ndt/gfu368] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 4.3] [Reference Citation Analysis]
222 Piras R, Iatropoulos P, Bresin E, Todeschini M, Gastoldi S, Valoti E, Alberti M, Mele C, Galbusera M, Cuccarolo P, Benigni A, Remuzzi G, Noris M. Molecular Studies and an ex vivo Complement Assay on Endothelium Highlight the Genetic Complexity of Atypical Hemolytic Uremic Syndrome: The Case of a Pedigree With a Null CD46 Variant. Front Med (Lausanne) 2020;7:579418. [PMID: 33224962 DOI: 10.3389/fmed.2020.579418] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
223 Schapiro D, Daga A, Lawson JA, Majmundar AJ, Lovric S, Tan W, Warejko JK, Fessi I, Rao J, Airik M, Gee HY, Schneider R, Widmeier E, Hermle T, Ashraf S, Jobst-Schwan T, van der Ven AT, Nakayama M, Shril S, Braun DA, Hildebrandt F. Panel sequencing distinguishes monogenic forms of nephritis from nephrosis in children. Nephrol Dial Transplant 2019;34:474-85. [PMID: 30295827 DOI: 10.1093/ndt/gfy050] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
224 Palma LMP, Eick RG, Dantas GC, Tino MKDS, de Holanda MI; Brazilian Thrombotic Microangiopathy and Atypical Hemolytic Uremic Syndrome Study Group (aHUS Brazil). Atypical hemolytic uremic syndrome in Brazil: clinical presentation, genetic findings and outcomes of a case series in adults and children treated with eculizumab. Clin Kidney J 2021;14:1126-35. [PMID: 33841858 DOI: 10.1093/ckj/sfaa062] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
225 Szarvas N, Szilágyi Á, Tasic V, Nushi-Stavileci V, Sofijanova A, Gucev Z, Szabó M, Szabó A, Szeifert L, Reusz G, Rusai K, Arbeiter K, Müller T, Prohászka Z. First-line therapy in atypical hemolytic uremic syndrome: consideration on infants with a poor prognosis. Ital J Pediatr 2014;40:101. [PMID: 25496981 DOI: 10.1186/s13052-014-0101-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
226 Verhave JC, Wetzels JF, van de Kar NC. Novel aspects of atypical haemolytic uraemic syndrome and the role of eculizumab. Nephrol Dial Transplant 2014;29 Suppl 4:iv131-41. [PMID: 25165180 DOI: 10.1093/ndt/gfu235] [Cited by in Crossref: 46] [Cited by in F6Publishing: 30] [Article Influence: 5.8] [Reference Citation Analysis]
227 Manrique-Caballero CL, Peerapornratana S, Formeck C, Del Rio-Pertuz G, Gomez Danies H, Kellum JA. Typical and Atypical Hemolytic Uremic Syndrome in the Critically Ill. Crit Care Clin 2020;36:333-56. [PMID: 32172817 DOI: 10.1016/j.ccc.2019.11.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
228 Cataland SR, Wu HM. How I treat: the clinical differentiation and initial treatment of adult patients with atypical hemolytic uremic syndrome. Blood 2014;123:2478-84. [PMID: 24599547 DOI: 10.1182/blood-2013-11-516237] [Cited by in Crossref: 86] [Cited by in F6Publishing: 61] [Article Influence: 10.8] [Reference Citation Analysis]
229 Bu F, Zhang Y, Wang K, Borsa NG, Jones MB, Taylor AO, Takanami E, Meyer NC, Frees K, Thomas CP, Nester C, Smith RJH. Genetic Analysis of 400 Patients Refines Understanding and Implicates a New Gene in Atypical Hemolytic Uremic Syndrome. J Am Soc Nephrol 2018;29:2809-19. [PMID: 30377230 DOI: 10.1681/ASN.2018070759] [Cited by in Crossref: 25] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
230 Nester CM, Smith RJ. Factors influencing treatment of atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 2014;9:1516-8. [PMID: 25135763 DOI: 10.2215/CJN.07540714] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
231 Goodship TH, Cook HT, Fakhouri F, Fervenza FC, Frémeaux-Bacchi V, Kavanagh D, Nester CM, Noris M, Pickering MC, Rodríguez de Córdoba S, Roumenina LT, Sethi S, Smith RJ; Conference Participants. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. Kidney Int 2017;91:539-51. [PMID: 27989322 DOI: 10.1016/j.kint.2016.10.005] [Cited by in Crossref: 256] [Cited by in F6Publishing: 226] [Article Influence: 42.7] [Reference Citation Analysis]
232 Fakhouri F, Loirat C. Anticomplement Treatment in Atypical and Typical Hemolytic Uremic Syndrome. Seminars in Hematology 2018;55:150-8. [DOI: 10.1053/j.seminhematol.2018.04.009] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 4.5] [Reference Citation Analysis]
233 Martin SM, Balestracci A, Puyol I, Toledo I, Cao G, Arizeta G. Uncommon Presentation of Atypical Hemolytic Uremic Syndrome: A Case Report. Indian J Nephrol 2021;31:478-81. [PMID: 34880559 DOI: 10.4103/ijn.IJN_271_20] [Reference Citation Analysis]
234 Quaggin SE. DGKE and atypical HUS. Nat Genet 2013;45:475-6. [PMID: 23619787 DOI: 10.1038/ng.2622] [Cited by in Crossref: 33] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
235 Scully M, Cataland S, Coppo P, de la Rubia J, Friedman KD, Kremer Hovinga J, Lämmle B, Matsumoto M, Pavenski K, Sadler E, Sarode R, Wu H; International Working Group for Thrombotic Thrombocytopenic Purpura. Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. J Thromb Haemost 2017;15:312-22. [PMID: 27868334 DOI: 10.1111/jth.13571] [Cited by in Crossref: 190] [Cited by in F6Publishing: 171] [Article Influence: 38.0] [Reference Citation Analysis]
236 Fidan K, Göknar N, Gülhan B, Melek E, Yıldırım ZY, Baskın E, Hayran M, Gülleroglu K, Özçakar ZB, Ozaltin F, Soylemezoglu O. Extra-Renal manifestations of atypical hemolytic uremic syndrome in children. Pediatr Nephrol 2018;33:1395-403. [PMID: 29610995 DOI: 10.1007/s00467-018-3933-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
237 Petruzziello-Pellegrini TN, Moslemi-Naeini M, Marsden PA. New insights into Shiga toxin-mediated endothelial dysfunction in hemolytic uremic syndrome. Virulence 2013;4:556-63. [PMID: 23955166 DOI: 10.4161/viru.26143] [Cited by in Crossref: 22] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
238 Raina R, Grewal MK, Radhakrishnan Y, Tatineni V, DeCoy M, Burke LL, Bagga A. Optimal management of atypical hemolytic uremic disease: challenges and solutions. Int J Nephrol Renovasc Dis 2019;12:183-204. [PMID: 31564951 DOI: 10.2147/IJNRD.S215370] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.7] [Reference Citation Analysis]
239 Lamari F, Saudubray J, Mitchell GA. Disorders of Intracellular Triglyceride and Phospholipid Metabolism. In: Saudubray J, Baumgartner MR, Walter J, editors. Inborn Metabolic Diseases. Berlin: Springer Berlin Heidelberg; 2016. pp. 477-91. [DOI: 10.1007/978-3-662-49771-5_34] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
240 Shatzel JJ, Taylor JA. Syndromes of Thrombotic Microangiopathy. Med Clin North Am 2017;101:395-415. [PMID: 28189178 DOI: 10.1016/j.mcna.2016.09.010] [Cited by in Crossref: 35] [Cited by in F6Publishing: 22] [Article Influence: 5.8] [Reference Citation Analysis]
241 Westland R, Bodria M, Carrea A, Lata S, Scolari F, Fremeaux-Bacchi V, D'Agati VD, Lifton RP, Gharavi AG, Ghiggeri GM, Sanna-Cherchi S. Phenotypic expansion of DGKE-associated diseases. J Am Soc Nephrol 2014;25:1408-14. [PMID: 24511134 DOI: 10.1681/ASN.2013080886] [Cited by in Crossref: 46] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
242 Bowen EE, Coward RJ. Advances in our understanding of the pathogenesis of hemolytic uremic syndromes. Am J Physiol Renal Physiol. 2018;314:F454-F461. [PMID: 29167171 DOI: 10.1152/ajprenal.00376.2017] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
243 Gulati A, Somlo S. Whole exome sequencing: a state-of-the-art approach for defining (and exploring!) genetic landscapes in pediatric nephrology. Pediatr Nephrol 2018;33:745-61. [PMID: 28660367 DOI: 10.1007/s00467-017-3698-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
244 Bray MA, Sartain SE, Gollamudi J, Rumbaut RE. Microvascular thrombosis: experimental and clinical implications. Transl Res 2020;225:105-30. [PMID: 32454092 DOI: 10.1016/j.trsl.2020.05.006] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 10.0] [Reference Citation Analysis]
245 Mannucci P, Cugno M. The complex differential diagnosis between thrombotic thrombocytopenic purpura and the atypical hemolytic uremic syndrome: Laboratory weapons and their impact on treatment choice and monitoring. Thrombosis Research 2015;136:851-4. [DOI: 10.1016/j.thromres.2015.09.007] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
246 So V, Jalan D, Lemaire M, Topham MK, Hatch GM, Epand RM. Diacylglycerol kinase epsilon suppresses expression of p53 and glycerol kinase in mouse embryo fibroblasts. Biochim Biophys Acta 2016;1861:1993-9. [PMID: 27713003 DOI: 10.1016/j.bbalip.2016.09.021] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
247 Zuber J, Le Quintrec M, Morris H, Frémeaux-Bacchi V, Loirat C, Legendre C. Targeted strategies in the prevention and management of atypical HUS recurrence after kidney transplantation. Transplant Rev (Orlando). 2013;27:117-125. [PMID: 23937869 DOI: 10.1016/j.trre.2013.07.003] [Cited by in Crossref: 56] [Cited by in F6Publishing: 51] [Article Influence: 6.2] [Reference Citation Analysis]
248 Zipfel PF, Wiech T, Rudnick R, Afonso S, Person F, Skerka C. Complement Inhibitors in Clinical Trials for Glomerular Diseases. Front Immunol 2019;10:2166. [PMID: 31611870 DOI: 10.3389/fimmu.2019.02166] [Cited by in Crossref: 39] [Cited by in F6Publishing: 31] [Article Influence: 13.0] [Reference Citation Analysis]
249 Hyvärinen S, Jokiranta TS. Minor Role of Plasminogen in Complement Activation on Cell Surfaces. PLoS One 2015;10:e0143707. [PMID: 26637181 DOI: 10.1371/journal.pone.0143707] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
250 Johnson S, Stojanovic J, Ariceta G, Bitzan M, Besbas N, Frieling M, Karpman D, Landau D, Langman C, Licht C, Pecoraro C, Riedl M, Siomou E, van de Kar N, Walle JV, Loirat C, Taylor CM. An audit analysis of a guideline for the investigation and initial therapy of diarrhea negative (atypical) hemolytic uremic syndrome. Pediatr Nephrol 2014;29:1967-78. [PMID: 24817340 DOI: 10.1007/s00467-014-2817-4] [Cited by in Crossref: 54] [Cited by in F6Publishing: 49] [Article Influence: 6.8] [Reference Citation Analysis]
251 Tsai H. A Mechanistic Approach to the Diagnosis and Management of Atypical Hemolytic Uremic Syndrome. Transfusion Medicine Reviews 2014;28:187-97. [DOI: 10.1016/j.tmrv.2014.08.004] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
252 Fomchenko EI, Duran D, Jin SC, Dong W, Erson-Omay EZ, Antwi P, Allocco A, Gaillard JR, Huttner A, Gunel M, DiLuna ML, Kahle KT. De novo MYH9 mutation in congenital scalp hemangioma. Cold Spring Harb Mol Case Stud 2018;4:a002998. [PMID: 29903892 DOI: 10.1101/mcs.a002998] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
253 Prakash S, Gharavi AG. Diagnosing kidney disease in the genetic era. Curr Opin Nephrol Hypertens 2015;24:380-7. [PMID: 26050126 DOI: 10.1097/MNH.0000000000000139] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
254 Feitz WJC, van de Kar NCAJ, Orth-Höller D, van den Heuvel LPJW, Licht C. The genetics of atypical hemolytic uremic syndrome. Med Genet 2018;30:400-9. [PMID: 30930551 DOI: 10.1007/s11825-018-0216-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
255 Challis RC, Araujo GS, Wong EK, Anderson HE, Awan A, Dorman AM, Waldron M, Wilson V, Brocklebank V, Strain L. A De Novo Deletion in the Regulators of Complement Activation Cluster Producing a Hybrid Complement Factor H/Complement Factor H-Related 3 Gene in Atypical Hemolytic Uremic Syndrome. J Am Soc Nephrol. 2016;27:1617-1624. [PMID: 26490391 DOI: 10.1681/asn.2015010100] [Cited by in Crossref: 26] [Cited by in F6Publishing: 16] [Article Influence: 3.7] [Reference Citation Analysis]
256 Palma LMP, Vaisbich-Guimarães MH, Sridharan M, Tran CL, Sethi S. Thrombotic microangiopathy in children. Pediatr Nephrol 2022. [PMID: 35041041 DOI: 10.1007/s00467-021-05370-8] [Reference Citation Analysis]
257 Kummeling GJ, Baas AF, Harakalova M, van der Smagt JJ, Asselbergs FW. Cardiovascular genetics: technological advancements and applicability for dilated cardiomyopathy. Neth Heart J 2015;23:356-62. [PMID: 26031632 DOI: 10.1007/s12471-015-0700-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
258 Ažukaitis K, Loirat C, Malina M, Adomaitienė I, Jankauskienė A. Macrovascular involvement in a child with atypical hemolytic uremic syndrome. Pediatr Nephrol 2014;29:1273-7. [PMID: 24352218 DOI: 10.1007/s00467-013-2713-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
259 Bozelli JC, Epand RM. Determinants of lipids acyl chain specificity: A tale of two enzymes. Biophysical Chemistry 2020;265:106431. [DOI: 10.1016/j.bpc.2020.106431] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
260 Phillips EH, Westwood JP, Brocklebank V, Wong EK, Tellez JO, Marchbank KJ, McGuckin S, Gale DP, Connolly J, Goodship TH, Kavanagh D, Scully MA. The role of ADAMTS-13 activity and complement mutational analysis in differentiating acute thrombotic microangiopathies. J Thromb Haemost 2016;14:175-85. [PMID: 26559391 DOI: 10.1111/jth.13189] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
261 Sim JA, Kim J, Yang D. Beyond Lipid Signaling: Pleiotropic Effects of Diacylglycerol Kinases in Cellular Signaling. Int J Mol Sci 2020;21:E6861. [PMID: 32962151 DOI: 10.3390/ijms21186861] [Reference Citation Analysis]
262 Fu W, Li M, Lin H, Xu Y, Han W, Chen H, Sun L. Cyclosporine A relieved proteinuria and hypoproteinemia in DGKE nephropathy. Clin Chim Acta 2021;518:78-82. [PMID: 33741360 DOI: 10.1016/j.cca.2021.02.021] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
263 Muff-Luett M, Nester CM. The Genetics of Ultra-Rare Renal Disease. J Pediatr Genet 2016;5:33-42. [PMID: 27617140 DOI: 10.1055/s-0036-1572515] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
264 Noris M, Remuzzi G. Cardiovascular complications in atypical haemolytic uraemic syndrome. Nat Rev Nephrol 2014;10:174-80. [DOI: 10.1038/nrneph.2013.280] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 5.1] [Reference Citation Analysis]
265 Yoshida Y, Kato H, Nangaku M. Atypical hemolytic uremic syndrome. Ren Replace Ther 2017;3. [DOI: 10.1186/s41100-016-0088-1] [Cited by in Crossref: 4] [Article Influence: 0.8] [Reference Citation Analysis]
266 Neave L, Gale DP, Cheesman S, Shah R, Scully M. Atypical haemolytic uraemic syndrome in the eculizumab era: presentation, response to treatment and evaluation of an eculizumab withdrawal strategy. Br J Haematol 2019;186:113-24. [PMID: 30916388 DOI: 10.1111/bjh.15899] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
267 Ipe TS, Lim J, Reyes MA, Ero M, Leveque C, Lewis B, Kain J. An extremely rare splice site mutation in the gene encoding complement factor I in a patient with atypical hemolytic uremic syndrome. J Clin Apher 2017;32:584-8. [PMID: 28455885 DOI: 10.1002/jca.21549] [Reference Citation Analysis]
268 Becker JU. Current status of pediatric renal transplant pathology. Pediatr Nephrol 2017;32:425-37. [PMID: 27221522 DOI: 10.1007/s00467-016-3381-x] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
269 Saha M, McDaniel JK, Zheng XL. Thrombotic thrombocytopenic purpura: pathogenesis, diagnosis and potential novel therapeutics. J Thromb Haemost 2017;15:1889-900. [PMID: 28662310 DOI: 10.1111/jth.13764] [Cited by in Crossref: 59] [Cited by in F6Publishing: 55] [Article Influence: 11.8] [Reference Citation Analysis]
270 Skerka C, Chen Q, Fremeaux-Bacchi V, Roumenina LT. Complement factor H related proteins (CFHRs). Mol Immunol. 2013;56:170-180. [PMID: 23830046 DOI: 10.1016/j.molimm.2013.06.001] [Cited by in Crossref: 145] [Cited by in F6Publishing: 130] [Article Influence: 16.1] [Reference Citation Analysis]
271 Bezdíčka M, Pavlíček P, Bláhová K, Háček J, Zieg J. Various phenotypes of disease associated with mutated DGKE gene. Eur J Med Genet 2020;63:103953. [PMID: 32413569 DOI: 10.1016/j.ejmg.2020.103953] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
272 Bu F, Maga T, Meyer NC, Wang K, Thomas CP, Nester CM, Smith RJ. Comprehensive genetic analysis of complement and coagulation genes in atypical hemolytic uremic syndrome. J Am Soc Nephrol 2014;25:55-64. [PMID: 24029428 DOI: 10.1681/ASN.2013050453] [Cited by in Crossref: 144] [Cited by in F6Publishing: 65] [Article Influence: 16.0] [Reference Citation Analysis]
273 Cheong HI, Jo SK, Yoon SS, Cho H, Kim JS, Kim YO, Koo JR, Park Y, Park YS, Shin JI, Yoo KH, Oh D. Clinical Practice Guidelines for the Management of Atypical Hemolytic Uremic Syndrome in Korea. J Korean Med Sci 2016;31:1516-28. [PMID: 27550478 DOI: 10.3346/jkms.2016.31.10.1516] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.4] [Reference Citation Analysis]
274 Sharma J, Lobo V, Singhal J, Anand S, Kadam S, Ranade S, Gangodkar P, Ganesan K, Phadke N, Agarwal M. Novel Mutations in the DGKE Gene in Two Indian Patients with Early-onset Atypical Haemolytic Uraemic Syndrome. Indian J Nephrol 2021;31:182-6. [PMID: 34267444 DOI: 10.4103/ijn.IJN_336_19] [Reference Citation Analysis]
275 Afshar-Kharghan V. COMPLEMENTing the diagnosis of aHUS. Blood 2014;124:1699-700. [PMID: 25214194 DOI: 10.1182/blood-2014-07-590356] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
276 Rodríguez de Córdoba S, Bernabéu C. Investigación multidisciplinar y traslacional en enfermedades raras. Arbor 2018;194:468. [DOI: 10.3989/arbor.2018.789n3010] [Reference Citation Analysis]
277 Kato H, Nangaku M, Hataya H, Sawai T, Ashida A, Fujimaru R, Hidaka Y, Kaname S, Maruyama S, Yasuda T, Yoshida Y, Ito S, Hattori M, Miyakawa Y, Fujimura Y, Okada H, Kagami S; Joint Committee for the Revision of Clinical Guides of Atypical Hemolytic Uremic Syndrome in Japan. Clinical guides for atypical hemolytic uremic syndrome in Japan. Pediatr Int. 2016;58:549-555. [PMID: 27460397 DOI: 10.1111/ped.13044] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.6] [Reference Citation Analysis]